Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers.

ABSTRACT: The majority of breast cancer specific deaths in women with estrogen receptor positive (ER⁺) tumors occur due to metastases that are resistant to therapy. There is a critical need for novel therapeutic approaches to achieve tumor regression and/or maintain therapy responsiveness in metastatic ER⁺ tumors. The objective of this study was to elucidate the role of metabolic pathways that undermine therapy efficacy in ER⁺ breast cancers. Our previous studies identified Exportin 1 (XPO1), a nuclear export protein, as an important player in endocrine resistance progression and showed that combining selinexor (SEL), an FDA-approved XPO1 antagonist, synergized with endocrine agents and provided sustained tumor regression. In the current study, using a combination of

SUBMITTER: Cotul EK 

PROVIDER: S-EPMC7563274 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature